Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Cho, Soo Min ^a,b   Kim, Hyunjin Vincent ^a,b   Lee, Sejin ^a,b   Kim, Hye Yun ^a,b,c   Kim, Woong ^a,b   Kim, Tae Song ^a   Kim, Dong Jin ^a   Kim, YoungSoo ^a,b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL; BLOOD; CEREBROSPINAL FLUID; DISEASE MODEL; MALE; MAZE TEST; MOUSE; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; MICE; PEPTIDE FRAGMENTS;

EID: 84945896478     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06777     Document Type: Article

References (25)

1. Koyama, A. et al. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 69, 824-831, doi:10.1001/archneurol.2011.1841 (2012).
2. Kang, D. E. et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106, 1159-1166, doi:10.1172/JCI11013 (2000).
3. Jovanovic, K. et al. Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease. Sci Rep 3, 2699, doi:10.1038/srep02699 (2013).
4. Yaffe, K. et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266, doi:10.1001/jama.2010.1995 (2011).
5. Song, F., Poljak, A., Smythe, G. A. & Sachdev, P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 61, 69-80, doi:10.1016/j.brainresrev.2009.05.003 (2009).
6. Pesini, P. et al. Reliable Measurements of the beta-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. Int J Alzheimers Dis 2012, 604141, doi:10.1155/2012/604141 (2012).
7. Fukumoto, H. et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60, 958-964, doi:10.1001/archneur.60.7.958 (2003).
8. Schupf, N. et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301, 199-203 (2001).
9. Tamaoka, A. et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141, 65-68 (1996).
10. Vanderstichele, H. et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258 (2000).
11. DeMattos, R. B. et al. Plaque-associated disruption of CSF and plasma amyloidbeta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81, 229-236 (2002).
12. Kawarabayashi, T. et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21, 372-381 (2001).
13. Van Dam, D. & De Deyn, P. P. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol 164, 1285-1300, doi:10.1111/j.1476-5381.2011.01299.x (2011).
14. Bryan, K. J., Lee, H., Perry, G., Smith, M. A. & Casadesus, G. in Methods of Behavior Analysis in Neuroscience Frontiers in Neuroscience (ed J. J. Buccafusco) (2009).
15. Jack, C. R., Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128, doi:10.1016/S1474-4422(09)70299-6 (2010).
16. Li, X. et al. Ratio of Abeta42/P-tau181p in CSF is associated with aberrant default mode network in AD. Sci Rep 3, 1339, doi:10.1038/srep01339 (2013).
17. Liu, L., Herukka, S. K., Minkeviciene, R., van Groen, T. & Tanila, H. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis 17, 516-523, doi:10.1016/j.nbd.2004.08.005 (2004).
18. Shibata, M. et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499, doi:10.1172/JCI10498 (2000).
19. Duran-Aniotz, C., Morales, R., Moreno-Gonzalez, I., Hu, P. P. & Soto, C. Brains from non-Alzheimer's individuals containing amyloid deposits accelerate Abeta deposition in vivo. Acta Neuropathol Commun 1, 76, doi:10.1186/2051-5960-1-76 (2013).
20. Maruyama, M. et al. Imaging of tau pathology in a tauopathymouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108, doi:10.1016/j.neuron.2013.07.037 (2013).
21. Azhdarzadeh, M. et al. Serum multivalent cationic pattern: speculation on the efficient approach for detection of Alzheimer's disease. Sci Rep 3, 2782, doi:10.1038/srep02782 (2013).
22. Choi, J. W., Kim, H. Y., Jeon, M., Kim, D. J. & Kim, Y. Efficient access to highly pure beta-amyloid peptide by optimized solid-phase synthesis. Amyloid 19, 133-137, doi:10.3109/13506129.2012.700287 (2012).
23. Maurice, T., Lockhart, B. P. & Privat, A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706, 181-193 (1996).
24. Haley, T. J. & McCormick, W. G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12, 12-15 (1957).
25. Liu, L. & Duff, K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp, doi:10.3791/960 (2008).